Navigation Links
Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
Date:9/24/2010

the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commerciall
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Echo Therapeutics, Inc. (NASDAQ: ECTE ... recent unauthorized public statements relating to Echo that have ... Shepard M. Goldberg, two members of the Echo Board ... the Echo Board by an affiliate of Platinum Management ... in numerous unauthorized public communications targeted at Echo stockholders, ...
(Date:10/2/2014)... 2014  Eli Lilly and Company (NYSE: LLY)  ... -- being studied for the treatment of systemic ... due to insufficient efficacy in two pivotal Phase ... safety concerns. ­­­­ In the ILLUMINATE ... endpoint, at either dose studied, of statistically significant ...
(Date:10/2/2014)... plc (NYSE: PRGO ; TASE), a public limited ... (the " Company "), today announced the expiration of ... of its new 1.30% Senior Notes due 2016 (the " ... Notes due 2018 (the " 2018 Exchange Notes "), $800,000,000 ... 2023 Exchange Notes ") and $400,000,000 of its new 5.30% ...
Breaking Medicine Technology:Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 2Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 3Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 4Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 2Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 4
... 5, 2007 - Australian,biotechnology company Avexa (ASX:AVX) announced ... which,represents the first 24 week segment of its ... open-label section of the,trial (weeks 24 to 48) ... day as part of their daily treatment regime.,The ...
... Primary endpoint achieved -- , LAINATE, Italy - ... today positive preliminary results from its,phase II/III study ... is a broad spectrum, semi-synthetic,antibiotic that is not ... of Cosmo's MMX(tm) technology, which delivers the active,ingredient ...
Cached Medicine Technology:Avexa's Apricitabine Clinical Trial Update 2Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2
(Date:10/2/2014)... PA (PRWEB) October 02, 2014 ... of the 2014 BIG Awards for Business program. ... and organizations with a proprietary judging process scored ... around the globe. , “The winners this year ... Russ Fordyce, Managing Director of the Business Intelligence ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, ... a neurotic personality style and prolonged stress may have ... suggests. Tracking 800 women over nearly four decades, ... jealous and moody -- which they defined as neurotic ... of developing Alzheimer,s compared to women scoring lowest in ...
(Date:10/2/2014)... By Steven Reinberg ... -- Living close to a major highway may raise your ... Among more than 5,000 postmenopausal women, those who lived within ... greater risk of developing high blood pressure than women living ... "The results of this study highlight the importance of our ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... have a total of 500 confirmed cases of Enterovirus D68, ... since the summer, U.S. health officials reported Wednesday. Four ... but it,s not clear what role -- if any -- ... officials are also trying to determine if the virus is ...
(Date:10/1/2014)... team of scientists has shown that more than 80 ... existing drugs. , The study found that medicines called ... a genetic mutation that is present in more than ... are currently used, or are in clinical trials, for ... disorders. , Bowel cancer is the second-most common cancer ...
Breaking Medicine News(10 mins):Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Eighty percent of bowel cancers halted with existing medicines 2
... movement, study finds, , , WEDNESDAY, Feb. 18 (HealthDay News) ... of their impaired physical abilities, even if it,s been ... paralysis on the right side after a stroke were ... hold and move objects after they participated in robot-assisted ...
... finds misdiagnosis risk goes up as age goes down , , ... of numbness at a Detroit emergency room was discharged after ... woman with sharp pain in her left eye and loss ... doctors that she had a migraine. , And a 29-year-old ...
... health complications , during National Eating Disorders Awareness WeekLISLE, ... wants to call attention to the dangers surrounding ... treatment during National Eating Disorders Awareness Week -- Feb. ... concern and can cause a variety of oral health ...
... this week,s Journal of the American Medical,Association ... of Bioinformatics at the National Institute of Statistical Sciences, ... statistical limitations of a study,claiming that bisphenol A is ... liver,enzyme levels. The earlier study, published in JAMA ...
... 18 Specialty Underwriters,Alliance, Inc. (Nasdaq: SUAI ... on Friday, March 6, 2009 at 11:00 a.m. Eastern ... year end results for 2008. Detailed,financial information will ... 2009. , Interested parties may ...
... Feb. 18 Monthly menstrual cycles ... can include cramps, headaches and bloating. With more ... dysmenorrhea, regular vomiting also is a symptom. This ... to a study in the November/December 2008 issue ...
Cached Medicine News:Health News:Working With Robots May Help After a Stroke 2Health News:ER Less Likely to Diagnose Stroke in Younger Folks 2Health News:ER Less Likely to Diagnose Stroke in Younger Folks 3Health News:Dentists Often First to Spot Eating Disorders in Patients 2Health News:Dentists Often First to Spot Eating Disorders in Patients 3Health News:Specialty Underwriters' Alliance, Inc. Announces Fourth Quarter and Year End 2008 Conference Call 2Health News:Women Only: Cramps, Bloating and Now, Tooth Erosion? 2Health News:Women Only: Cramps, Bloating and Now, Tooth Erosion? 3
Diamond Point Bone Probe with Ortho-Grip® silicone rubber palm style handles and,stainless steel impactor caps....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Steroid eluting pacemaker leads...
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Medicine Products: